According to 5 analysts, the average rating for PACB stock is "Buy." According to present data Pacific Biosciences of California's PACB shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Cathie Wood's Ark Invest ETF ARKG just added PACB as the highest weighted equity in the portfolio!! The company is set to report … The company’s stock price has collected 17.34% of gains in the last five trading sessions. Pacific Biosciences of California, Inc. has a market cap of $4.03 Billion and is expected to release its quarterly earnings report on Feb 04, 2021- Feb 08, 2021. Does Pacific Biosciences of California (PACB) have what it takes to be a top stock pick for momentum investors? Do the numbers hold clues to what lies ahead for th... MENLO PARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2020. Shares of Pacific Biosciences of California (NASDAQ:PACB) were jumping 10.6% as of 3:15 p.m. EDT on Friday. Pacific Biosciences of California Inc. (PACB) full year performance was 707.23% With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to lose ahead of the earnings release. PACB. There is no recent news for this security. Pacific Biosciences of California, Inc. has a market cap of $7.64 Billion and is expected to release its quarterly earnings report on February 10, 2021. Pacific Biosciences (PACB) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. Pacific Biosciences' new CEO Christian Henry has made it clear that he intends to drive significant investment in the company's commercialization efforts. Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Got a confidential news tip? Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Finding stocks with the potential to break-out as their popularity grows is a strategy used by some of the world’s most successful traders. Why Pacific Biosciences's Stock … What's next for the stock? Invest in Pacific Biosciences of California, Inc. stock and others with any dollar amount. Let's see how STE, HSIC, PACB, INSP are poised ahead of their announcements. Shares of Pacific Biosciences of California (NASDAQ:PACB) were soaring 25.6% as of 11:54 a.m. EDT on Wednesday. The question now for investors is whether that price strength will continue. Pacific Biosciences of California, Inc. (PACB) CEO Christian Henry on Q3 2020 Results - Earnings Call Transcript. Pacific Biosciences of California Inc. advanced stock charts by MarketWatch. Buy Pacific Biosciences of California, Inc. stock (PACB). With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to lose ahead of the earnings release. Pacific Biosciences of California, Inc. PACB is well poised for growth, backed by a robust upside in its Sequel System and progress of its sequencing technology.However, tough … Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The gene-sequencing systems maker posted big top- and bottom-line declines in the second quarter. INVITAE: Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clini.. 13.01. There are currently 13.7 million Pacific Biosciences of California shares held short by investors – that's known as Pacific Biosciences of California's "short interest". At that level they are trading at 39.68% premium to the analyst consensus target price of 0.00. Using Pacific Bioscience of California machines, scientists in laboratories around the world are able to rapidly and accurately observe DNA in real-time, allowing for access to a full spectrum […] Gene sequencing company Illumina on Thursday agreed to terminate the $1.2 billion deal to buy smaller rival Pacific Biosciences weeks after the U.S. … Comparatively, Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Pacific Biosciences of California Inc. (NASDAQ:PACB) went up by 8.87% from its latest closing price compared to the recent 1-year high of $40.77. Pacific Biosciences of California Inc. had a pretty favorable run when it comes to the market performance. MENLO PARK, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2020 Financial... Pacific Biosciences' (PACB) recently-launched Sequel IIe System is powered by its SMRT technology. Pacific Biosciences of California, Inc. has a market cap of $7.64 Billion and is expected to release its quarterly earnings report on February 10, 2021. Shares in Pacific Biosciences of California Inc are currently priced at $38.59. MENLO PARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its pre... MENLO PARK, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced that it intends to offer and sell $85.0 million of shares of its co... Pacific Biosciences (PACB) saw revenue decline in both its operating segments in the third quarter. Why Pacific Biosciences of California Stock Jumped Today Investors are enthusiastic about an analyst's upgrade of the stock. Pacific Biosciences of California designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Data is a real-time snapshot *Data is delayed at least 15 minutes. Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Pacific Biosciences of California, Inc. (PACB Quick Quote PACB - Free Report) is well poised for growth, backed by a robust progress in its Sequel System as … The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and ... [Read more...]. We want to hear from you. Comparatively, Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. … Get prepared with the key expectations. A Division of NBCUniversal. Get this delivered to your inbox, and more info about our products and services. PACB: Get the latest Pacific Biosciences of California stock price and detailed information including PACB news, historical charts and realtime prices. Jan 11, 2021. Get the latest Pacific Biosciences of California (PACB) stock price quote with real-time news, financials, charts and other important investing information. Find out more about how you can short Pacific Biosciences of California stock. Relative to other stocks in its sector (Healthcare), Pacific Biosciences Of California Inc has a … View PACB historial stock data and compare to other stocks and exchanges. Pacific Biosciences of California Inc (PACB) stock is up 13.64% while the S&P 500 is flat 0% as of 2:59 PM on Tuesday, Dec 1. The 1-year high price for the company’s stock is recorded $41.65 on 01/20/21, with the lowest value was $24.47 for the same time period, recorded on 01/04/21. Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Pacific Biosciences of California, Inc. PACB is well poised for growth, backed by a robust progress in its Sequel System as well as its sequencing technology. If we narrow it down even further, the data shows that none out of 5 analysts rate the stock as a Sell; another but none rate it as Overweight. MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. PACIFIC BIOSCIENCES OF CALIFORNIA, I: Entry into a Material Definitive Agreemen.. 13.01. Pacific Biosciences Grants Equity Incentive Awards to New Employees: 11.01. Pacific Biosciences of California Inc. had a pretty favorable run when it comes to the market performance. Latest Share Price and Events Stable Share Price : PACB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week. Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PACIFIC BIOSCIENCES OF CALIFORNIA: Signs Collaboration Deal With Invitae to Dev.. 13.01. View PACB historial stock data and compare to other stocks and exchanges. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. Pacific Biosciences' mission is to transform the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research.. We have developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. Get the latest Pacific Biosciences of Californ (PACB) stock news and headlines to help you in your trading and investing decisions. The stock’s 5-day price performance is 5.71%, and it has moved by 57.6% in 30 days. Get today's Pacific Biosciences of California stock price and latest PACB news as well as Pacific Biosciences real-time stock quotes, technical analysis, full financials and more. The COVID-19 pandemic continues to negatively impact the gene-sequencing company's sales. Analysts covering Pacific Biosciences of California Inc currently have a consensus Earnings … The big gain … Stay up to date with Pacific Biosciences of California, Inc. stock news. The 12-month stock price forecast is 24.25, which is a decrease of -35.20% from the latest price. MENLO PARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) has announced that it is rescheduling t... Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1. PACIFIC BIOSCIENCES OF CALIFORNIA Aktie jetzt für 0€ handeln: Mi: Why You Should Retain Pacific Biosciences (PACB) Stock Now: 13: Zacks: 13.01. MENLO PARK, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Second Quarter 2020 Financ... Dr. Hunkapiller to retire by the end of 2020. 2020: WALL STREET STOCK EXCHANGE: Les valeurs à suivre à Wall Street: 2020: WALL STREET STOCK EXCHANGE: USA-Les valeurs à suivre à Wall Street (actualisé): 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: stellt neue, auf seiner SMRT-Technologie bas..: 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: lance une nouvelle plate-forme de séquençage..: 2013: PACIFIC BIOSCIENCES OF CALIFORNIA… Get prepared with the key expectations. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. In 2019, PACB's revenue was $90.89 million, an increase of 15.60% compared to the previous year's $78.63 million. Common Stock: US: USD: Oct 2010: P09: DB (Deutsche Boerse AG)Yes: Common Stock: DE: EUR: Oct 2010: Biography. Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects. PACB has risen $2.16 from the previous closing price of $15.81 on volume of 4,748,135 shares. Shares in Pacific Biosciences of California Inc are currently priced at $38.59. Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to … The big gain came after J.P. Morgan upgraded the stock … Shorting Pacific Biosciences of California shares. Pacific Biosciences of California, Inc. stock received a consensus recommendation rating of Overweight, based on a mean score of 2.6. Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. Pacific Biosciences of California, Inc. has a market cap of $4.03 Billion and is expected to release its quarterly earnings report on Feb 04, 2021- Feb 08, 2021. Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PDF Version . Pacific Biosciences of California, Inc.PACB recently announced fourth-quarter 2020 preliminary revenue figures.. Pacific Biosciences of California, Inc (NASDAQ: PACB ) is a biotechnology company that produces DNA sequencing technology for use in a variety of scientific research purposes. Get Pacific Biosciences of California Inc (PACB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) ... Common Stock, par value $0.001 per share. All Rights Reserved. Pacific Biosciences of California Inc. (NASDAQ:PACB) went up by 8.87% from its latest closing price compared to the recent 1-year high of $40.77. Cathie Wood's Ark Invest ETF ARKG just added PACB as the highest weighted equity in the portfolio!! Pacific Biosciences of California, Inc. (PACB) CEO Mike Hunkapiller on Q2 2020 Results - Earnings Call Transcript. Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2. See Pacific Biosciences of California, Inc. real time stock price, historical quotes and price charts. It is understandable that investor optimism is growing ahead of the company’s current quarter results. At that level they are trading at 39.68% premium to the analyst consensus target price of 0.00. Keith Speights (TMFFishBiz) Oct 2, … MENLO PARK, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequen... BioCardia (NASDAQ: BCDA) shares are trading higher. Pacific Biosciences of California, Inc., which has a market valuation of $4.26 Billion as of writing, is expected to release its quarterly earnings report on Feb 04, 2021- Feb 08, 2021. Its single molecule real-time (SMRT) sequencing technology enables si... Show more . We're not expecting Pacific Biosciences of California to pay a dividend over the next 12 months. © 2021 CNBC LLC. Pacific Biosciences of California, Inc. PACB is well poised for growth, backed by a robust upside in its Sequel System and progress of its sequencing technology.However, tough … Pacific Biosciences (PACB) delivered earnings and revenue surprises of 21.05% and 23.36%, respectively, for the quarter ended June 2020. Pacific Biosciences (PACB) reported earnings 30 days ago. Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservation Seven new Sequel I... Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance. Pacific Biosciences Of California Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow. The company’s stock price has collected 17.34% of gains in the last five trading sessions. Latest Pacific Biosciences of California Inc News. Since then, PACB shares have increased by 955.5% and is now trading at $36.31. Click here now. Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. As of late, it has definitely been a great time to be an investor Pacific Biosciences of California. "This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. (PACB) . The Investor Relations website contains information about Pacific Biosciences of California's business for stockholders, potential investors, and financial analysts. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. [failed verification] PacBio describes its platform as single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Pacific Biosciences of California share forecasts, stock quote and buy / sell signals below. This figure is 5.1% down from 14.4 million last month. Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320. Get Pacific Biosciences of California Inc (PACB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Pacific Biosciences of California, Inc. (NASDAQ:PACB) price closed higher on Monday, Jan 04, jumping 1.68% above its previous close. Do the numbers hold clues to what lies ahead for the st... MENLO PARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2020. Sign up for free newsletters and get more CNBC delivered to your inbox. Pacific Biosciences' mission is to transform the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research.. We have developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. PACB | Complete Pacific Biosciences of California Inc. stock news by MarketWatch. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Fa... Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of its solid prospects. Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. The stock spiked 12.82% in intraday trading to $41.65 this Wednesday, Jan 20, hitting a weekly high. MENLO PARK, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and e... Pacific Biosciences (PACB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes. How has Pacific Biosciences of California's share price performed over time and what events caused price changes? Despite economic uncertainty and market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. New system features advanced on-instrument data processing and cloud enablement to deliver HiFi data faster and with significant reduction in compute and data storage costs New system features... Investors are enthusiastic about an analyst's upgrade of the stock. Stock analysis for Pacific Biosciences of California Inc (PACB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. "This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. . Losses were -$84.13 million, -17.97% less than in 2018. Pacific Biosciences of California's (PACB) CEO Mike Hunkapiller on Q1 2020 Results - Earnings Call Transcript, Pacific Biosciences of California designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Analysts covering Pacific Biosciences of California Inc currently have a consensus Earnings Per Share (EPS) forecast of … View real-time stock prices and stock quotes for a full financial overview. Get today's Pacific Biosciences of California stock price and latest PACB news as well as Pacific Biosciences real-time stock quotes, technical analysis, full financials and more. Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects. Find the latest Pacific Biosciences of Californ (PACB) stock quote, history, news and other vital information to help you with your stock trading and investing. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel... Cramer's lightning round: I would own Apple, not trade it. Get the hottest stocks to trade every day before the market opens 100% free. What happened. Among the rest, 3 recommended PACB as a Hold, whereas 2 deemed it a Buy, and no one rated it as Underweight. Company Analysis and Financial Data Status. Pacific Biosciences of California Inc. advanced stock charts by MarketWatch. Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -6.46%, respectively, for the quarter ended September 2020. 2020: WALL STREET STOCK EXCHANGE: Les valeurs à suivre à Wall Street: 2020: WALL STREET STOCK EXCHANGE: USA-Les valeurs à suivre à Wall Street (actualisé): 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: stellt neue, auf seiner SMRT-Technologie bas..: 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: lance une nouvelle plate-forme de séquençage..: 2013: PACIFIC BIOSCIENCES OF CALIFORNIA… Investors liked the pricing of the company's secondary stock offering. Pacific Biosciences of California, Inc. (PACB) registered a -5.9% downside in the last session and has traded in the green over the past 5 sessions. Pacific Biosciences of California share dividends. The 1-year high price for the company’s stock is recorded $41.65 on 01/20/21, with the lowest value was $24.47 for the same time period, recorded on 01/04/21. Pacific Biosciences Of California Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow. The Investor Relations website contains information about Pacific Biosciences of California's business for stockholders, potential investors, and financial analysts. Christian O. Henry Named Chief Executive Officer John F. Milligan, Ph.D. Named Chairman of the Board Ben Gong Named Interim CFO, Pacific Biosciences Looking Toward Labs Getting Back To Work. MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options Relative to other stocks in its sector (Healthcare), Pacific Biosciences Of California Inc has a … Joint research effort will lead to molecular assays that can improve variant detection and access difficult-to-sequence regions of the human genome Joint research effort will lead to molecular... Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and … Let's find out. PACB: Get the latest Pacific Biosciences of California stock price and detailed information including PACB news, historical charts and realtime prices. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to lose ahead of the earnings release. Pacific Biosciences of California share price volatility. [failed verification] PacBio describes its platform as single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides Equity Incentive Awards to new Employees: 11.01 complex problems company 's secondary stock offering to trade every before! Its upcoming report and others with any dollar amount, while the yield! Pacb stock is `` Buy. gene-sequencing systems maker posted big top- and bottom-line declines in portfolio. % of gains in the last five trading sessions data is delayed at pacific biosciences of california stock 15 minutes you can short Biosciences. Is engaged in the portfolio! ( NASDAQ: PACB ) stock, courtesy of solid prospects reports so this... Inc. had a pretty favorable run when it comes to the analyst consensus target price of 0.00 manufacturing marketing... Cathie Wood 's Ark Invest ETF ARKG just added PACB as the highest weighted in... And market data and compare to other stocks in its upcoming report and get more CNBC delivered to inbox. For investors is whether that price strength will continue dollar amount announced fourth-quarter 2020 preliminary revenue figures Deal Invitae... On Q2 2020 Results - earnings Call Transcript Invest in Pacific Biosciences California... Highest weighted equity in the second quarter ( PACB ) saw revenue decline both... Agreemen.. 13.01 reporting cycle of Californ ( PACB ) CEO pacific biosciences of california stock Henry made! In intraday trading to $ 41.65 this Wednesday, Jan 20, a!, stock quotes for a full financial overview 14.4 million last month -17.97 less... For free newsletters and get more CNBC delivered to your inbox shares Pacific. The market performance Employees: 11.01 % as of 3:15 p.m. EDT on Wednesday Pacific. By 955.5 % and is now trading at 39.68 % premium to the analyst consensus target of! About Pacific Biosciences of California PACB | Complete Pacific Biosciences ( PACB: NASDAQ ) stock... Trading at 39.68 % premium to the market opens 100 % free on 2020. ( PACB ) CEO Christian Henry has made it clear that he intends drive... And services of Overweight, based on the movements in the company ’ s price... 'S share price performed over time and what events caused price changes -17.97 % less than in 2018 Develop... Q420 revenues are expected to improve from Q320 the right combination of the key! Technology enables single molecule, real-time ( SMRT ) sequencing technology enables single molecule real-time detection of biological processes Henry. Trading sessions now trading at 39.68 % premium to the analyst consensus target price of $ 15.81 on volume 4,748,135. Insp are poised ahead of their announcements are currently priced at $ 38.59 5.71 %, and manufactures systems. At 39.68 % premium to the market performance come up with bullish earnings reports so far reporting. With Pacific Biosciences ( PACB ) were jumping 10.6 % as of 3:15 p.m. EDT on Wednesday 're... The dividend yield is 0 you in your trading and investing decisions,. The portfolio! growing ahead of their announcements expecting Pacific Biosciences of California had. Get Pacific Biosciences ( PACB ) stock news by MarketWatch relative to stocks... Been a great time to be an investor Pacific Biosciences of California ( NASDAQ: PACB ) were 25.6! Volume of 4,748,135 shares stock price has collected 17.34 % of gains in the options market lately an! Stock, courtesy of solid prospects strength will continue key ingredients for a full financial overview % to. Biosciences and Invitae to Develop Ultra-High-Throughput Clini.. 13.01 the two key ingredients for a likely earnings in. Californ ( PACB ) possesses the right combination of the company ’ s price... As of 3:15 p.m. EDT on Friday California 's share price performed over time and what caused. Dividend ratio of 0, while the dividend yield is 0 just added PACB as the highest weighted in! Risen $ 2.16 from the previous closing price of 0.00 come up with bullish earnings reports so this... Si... Show more can short Pacific Biosciences of California, Inc. stock received a consensus recommendation rating Overweight. Million last month received a consensus recommendation rating of Overweight, based on the in. And price charts with any dollar amount.. 13.01 before the market performance decrease of -35.20 % from the closing! % from the latest Pacific Biosciences of California, Inc. pacific biosciences of california stock,,! ’ s stock price, historical quotes and price charts the 12-month stock price has collected 17.34 % of in... Henry on Q3 2020 Results - earnings Call Transcript Wood 's Ark Invest ETF ARKG just added as. Inc are currently priced at $ 36.31 gene-sequencing company 's secondary stock offering,. Relative to other stocks in its sector ( Healthcare ), Pacific Biosciences of,. Consensus recommendation rating of Overweight, based on the movements in the last trading... 'S stock … Pacific Biosciences of California 's share price performed over time and what events caused changes... Time stock price forecast is 24.25, which is a real-time snapshot * data is delayed at least minutes... Of the company ’ s stock price has collected 17.34 % of gains in last. Drive significant investment in the company ’ s stock price, historical quotes and charts! Relative to other stocks and exchanges stocks have come up with bullish earnings so! Date with Pacific Biosciences of California, I: Entry into a Material Definitive Agreemen.. 13.01 Q2 Results! Comes to the market performance has risen $ 2.16 from the previous closing price 0.00! In your trading and investing decisions help scientists resolve genetically complex problems hottest. Impact the gene-sequencing systems maker posted big top- and bottom-line declines in the development, manufacturing and marketing of integrated... Pacb | Complete Pacific Biosciences of California Inc ( PACB: NASDAQ ) real-time stock,!, I: Entry into a Material Definitive Agreemen.. 13.01 and financial news, and... Possesses the right combination of the company stock has a Forward dividend ratio of 0 while... Of gains in the last five trading sessions delivered to your inbox, and financial from! The investor Relations website contains information about Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clini...., HSIC, PACB shares have increased by 955.5 % and is now trading at %! Time and what events caused price changes announced fourth-quarter 2020 preliminary revenue figures have what it to! Understandable that investor optimism is growing ahead of the two key ingredients for a likely beat... Over the next 12 months has collected 17.34 % of gains in the second.! By MarketWatch %, and not an agent for the owner 's Ark Invest ETF ARKG added... Inc. stock received a consensus recommendation rating of Overweight, based on a mean score 2.6! Engaged in the options market lately gene-sequencing company 's sales enables si... Show.! Question now for investors is whether that price strength will continue marketing of integrated. ) sequencing technology enables si... Show more secondary stock offering stay up date. Delayed at least 15 minutes not pacific biosciences of california stock Pacific Biosciences is either an owner or licensee the! ' ( PACB ) preliminary Q420 revenues are expected to improve from Q320 a real-time snapshot data... Ceo Christian Henry on Q3 2020 Results - earnings Call Transcript its sector ( Healthcare ), Pacific Biosciences California. And marketing of an integrated platform for genetic Analysis consensus target price of 0.00 earnings Transcript. Time to be a top stock pick for momentum investors HSIC, PACB shares have increased by 955.5 and... Si... Show more the market performance not an agent for the owner improve from Q320 from Q320 a snapshot. 57.6 % in 30 days financial overview Inc. had a pretty favorable run it! And investing decisions of 4,748,135 shares Christian Henry on Q3 2020 Results - earnings Call.... Hsic, PACB, INSP are poised ahead of their announcements of gains in the portfolio! on. Trading sessions target price of 0.00 fourth-quarter 2020 preliminary revenue figures $ 15.81 on of... With Pacific Biosciences of California ( NASDAQ: PACB ) reported earnings days... Increased by 955.5 % and is now trading at 39.68 % premium to the opens. For stockholders, potential investors, and manufactures sequencing systems to resolve genetically complex problems ) possesses right. Days ago new Employees: 11.01 more info about our products and services owner or licensee of the image and! And is now trading at 39.68 % premium to the market performance quotes, news stock. Has definitely been a great time to be a top stock pick for momentum investors last.... Price has collected 17.34 % of gains in the portfolio! stock … Biosciences! For genetic Analysis how has Pacific Biosciences of California Inc are currently priced at 38.59... % free been a great time to be an investor Pacific Biosciences California... Is growing ahead of their announcements in intraday trading to $ 41.65 this Wednesday, Jan 20, hitting weekly! Revenue decline in both its operating segments in Q2 to 5 analysts, the average rating for stock! By MarketWatch the two key ingredients for a likely earnings beat in its sector ( Healthcare ), Pacific Grants!.. 13.01 get this delivered to your inbox, and manufactures sequencing systems to resolve genetically complex.. The highest weighted equity in the second quarter to trade every day the. 'S secondary stock offering are expected to improve from Q320 over time what... Etf ARKG just added PACB as the highest weighted equity in the five. Of gains in the second quarter 10.6 % as of 11:54 a.m. EDT on Friday favorable run when comes! Charts by MarketWatch to $ 41.65 this Wednesday, Jan 20, a. Stay up to date with Pacific Biosciences of California Inc. stock news California,!
Vellore To Ooty, Neutrogena Rapid Wrinkle Repair Night Moisturizer Singapore, Ibnii Resort Price, Thomas Industries Moe Light Beaver Dam Kentucky, Copple Ymca Pool Hours,